Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tetrahydrobiopterin (BH4)-binding site is a critical functional region within all isoforms of nitric oxide synthase (NOS). It specifically binds the cofactor tetrahydrobiopterin, which is essential for NOS catalytic activity and proper enzyme function. BH4 participates directly in electron transfer during catalysis and stabilizes the active dimeric form of NOS required for NO production. The binding site is located within the N-terminal oxygenase domain of NOS, adjacent to the heme group. Disruption of the BH4-binding site leads to enzyme uncoupling, resulting in superoxide rather than NO production, contributing to oxidative stress implicated in cardiovascular disease and other conditions. Certain inhibitors like 7-nitroindazole can competitively inhibit both arginine and tetrahydrobiopterin binding. Proper function of this site is crucial for physiological NO production.
Competitive inhibition of tetrahydrobiopterin and L-arginine binding
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetrahydrobiopterin-binding site of nitric oxide synthase.